Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells
- Authors:
- Zhewen Dong
- Wenxiang Zhang
- Siyu Chen
- Chang Liu
-
Affiliations: Jiangsu Key Laboratory for Molecular Medical Biotechnology and School of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, P.R. China, State Key Laboratory of Natural Medicines and School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China - Published online on: June 5, 2019 https://doi.org/10.3892/mmr.2019.10344
- Pages: 1383-1392
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H and Martin C: Familial hypercholesterolemia: The most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 19(pii): E34262018. View Article : Google Scholar : PubMed/NCBI | |
|
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, . The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1383–1389. 1994.PubMed/NCBI | |
|
Golomb BA and Evans MA: Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 8:373–418. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L and Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 24:1454–1459. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gouni-Berthold I: PCSK9 antibodies: A new class of lipid-lowering drugs. Atheroscler Suppl. 18:21–27. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Horton JD, Cohen JC and Hobbs HH: Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem Sci. 32:71–77. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Goldstein JL and Brown MS: A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 161:161–172. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, et al: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 14:413–419. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, et al: Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 282:20502–20512. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC and Hobbs HH: Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 282:18602–18612. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 34:154–156. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Maxwell KN and Breslow JL: Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol. 16:167–172. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, et al: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat. 26:4972005. View Article : Google Scholar : PubMed/NCBI | |
|
Hallman DM, Srinivasan SR, Chen W, Boerwinkle E and Berenson GS: Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am J Cardiol. 100:69–72. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fala L: Repatha (Evolocumab): Second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia. Am Health Drug Benefits 9 (Spec Feature). 136–139. 2016. | |
|
Raedler LA: Praluent (Alirocumab): First PCSK9 inhibitor approved by the FDA for hypercholesterolemia. Am Health Drug Benefits 9 (Spec Feature). 123–126. 2016. | |
|
White CM: Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab. Ann Pharmacother. 49:1327–1335. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dai L, Lu A, Zhong LLD, Zheng G and Bian Z: Chinese herbal medicine for hyperlipidaemia: A review based on data mining from 1990 to 2016. Curr Vasc Pharmacol. 15:520–531. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 10:1344–1351. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Dong B, Li H, Singh AB, Cao A and Liu J: Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 290:4047–4058. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Flora K, Hahn M, Rosen H and Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 93:139–143. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Wellington K and Jarvis B: Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs. 15:465–489. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Saller R, Meier R and Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs. 61:2035–2063. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zi X and Agarwal R: Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA. 96:7490–7495. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E and Scambia G: Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer. 39:2403–2410. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Saliou C, Rihn B, Cillard J, Okamoto T and Packer L: Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett. 440:8–12. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Dong B, Park SW, Lee HS, Chen W and Liu J: Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 284:28885–28895. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B and Krempf M: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 281:6211–6218. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ko FN, Chu CC, Lin CN, Chang CC and Teng CM: Isoorientin-6′-O-glucoside, a water-soluble antioxidant isolated from Gentiana arisanensis. Biochim Biophys Acta. 1389:81–90. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lu CL, Zhu W, Wang DM, Chen WL, Hu MM, Wang M, Xu XJ and Lu CJ: Inhibitory effects of chemical compounds isolated from the rhizome of Smilax glabra on nitric oxide and tumor necrosis factor-α production in lipopolysaccharide-induced RAW264.7 cell. Evid Based Complement Alternat Med. 2015:6024252015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Jung SH, Lee YS, Yamada M, Kim BK, Ohuchi K and Shin KH: Antiinflammatory activity of hyperin from Acanthopanax chiisanensis roots. Arch Pharm Res. 27:628–632. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Su JP, Bai Y, Li J and Liu YH: Inhibitory effects of O-methylated isoflavone glycitein on human breast cancer SKBR-3 cells. Int J Clin Exp Pathol. 8:7809–7817. 2015.PubMed/NCBI | |
|
Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, Nishino H and Aoike A: Genistein arrests cell cycle progression at G2-M. Cancer Res. 53:1328–1331. 1993.PubMed/NCBI | |
|
Chen J, Zhao X, Ye Y, Wang Y and Tian J: Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by Calycosin and Formononetin. Cell Physiol Biochem. 32:1790–1797. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Auyeung KK, Law PC and Ko JK: Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncol Rep. 28:2188–2194. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Fang L, Liu F, Zong C, Cai R, Chen X and Qi Y: Suppressive effects of irisflorentin on LPS-induced inflammatory responses in RAW 264.7 macrophages. Exp Biol Med (Maywood). 239:1018–1024. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Effect of Dichotomitin on relieving cough induced by cigarette and infection and serum cytokines of model guinea pigs. Zhonghua Zhongyiyao Xuekan. 34:2902–2904. 2016. | |
|
Jun HJ, Hoang MH, Lee JW, Yaoyao J, Lee JH, Lee DH, Lee HJ, Seo WD, Hwang BY and Lee SJ: Iristectorigenin B isolated from Belamcanda chinensis is a liver X receptor modulator that increases ABCA1 and ABCG1 expression in macrophage RAW 264.7 cells. Biotechnol Lett. 34:2213–2221. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CC, Chen CY, Ueng SH, Hsueh C, Yeh CT, Ho JY, Chou LF and Wang TH: Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis. 9:5432018. View Article : Google Scholar : PubMed/NCBI | |
|
Martineti V, Tognarini I, Azzari C, Carbonell Sala S, Clematis F, Dolci M, Lanzotti V, Tonelli F, Brandi ML and Curir P: Inhibition of in vitro growth and arrest in the G0/G1 phase of HCT8 line human colon cancer cells by kaempferide triglycoside from Dianthus caryophyllus. Phytother Res. 24:1302–1308. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CM, Huang ST, Liang YC, Lin MS, Shih CM, Chang YC, Chen TY and Chen CT: Isovitexin suppresses lipopolysaccharide-mediated inducible nitric oxide synthase. Planta Med. 71:748–753. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zygmunt K, Faubert B, MacNeil J and Tsiani E: Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. Biochem Biophys Res Commun. 398:178–183. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Niu X, Xing W, Li W, Fan T, Hu H and Li Y: Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway. Int Immunopharmacol. 14:164–171. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shyu MH, Kao TC and Yen GC: Oleanolic acid and ursolic acid induce apoptosis in HuH7 human hepatocellular carcinoma cells through a mitochondrial-dependent pathway and downregulation of XIAP. J Agric Food Chem. 58:6110–6118. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ko BS, Choi SB, Park SK, Jang JS, Kim YE and Park S: Insulin densitizing and insulinotropic sction of Berberine from Cortidis Rhizoma. Biol Pharm Bull. 28:1431–1437. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tang FY, Su YC, Chen NC, Hsieh HS and Chen KS: Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol Nutr Food Res. 52:683–691. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fryer LG, Parbu-Patel A and Carling D: The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 277:25226–25232. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Cui Q, Tashiro S, Onodera S, Minami M and Ikejima T: Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 30:859–864. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Miyoshi K, Kasahara K, Miyazaki I and Asanuma M: Factors that influence primary cilium length. Acta Med Okayama. 65:279–185. 2011.PubMed/NCBI | |
|
Li X, Liu Y, Hou X, Peng H, Zhang L, Jiang Q, Shi M, Ji Y, Wang Y and Shi W: Chlorogenic acid inhibits the replication and viability of enterovirus 71 in vitro. PLoS One. 8:e760072013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang CJ and Yu HT: The signal pathways of immune inflammation mediated By The Tlr3/Nf-Kappab and activator protein-1 in cells infected with influenza A virus antagonized by Baicalin. Adv Mat Res. 345:201–209. 2012. | |
|
Ida C, Ogata S, Okumura K and Taguchi H: Changes in the gene expression of C-myc and CD38 in HL-60 cells during differentiation induced by nicotinic acid-related compounds. Biosci Biotechnol Biochem. 72:868–871. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Jiang M, Zhang L, Jian Y, Zhang G, Du B, Ren Y, Li X and Yao J: Cycloastragenol mediates activation and proliferation suppression in concanavalin A-induced mouse lymphocyte pan-activation model. Immunopharmacol Immunotoxicol. 39:131–139. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Sun YY, Sun MY, Mao WA, Wang L, Zhang J and Zhang H: Prim-O-glucosylcimifugin attenuates lipopolysaccharide induced inflammatory response in RAW 264.7 macrophages. Pharmacogn Mag. 13:378–384. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu TZ, Chen CY, Yiin SJ, Chen CH, Cheng JT, Shih MK, Wang YS and Chern CL: Molecular mechanism of cell cycle blockage of hepatoma SK-Hep-1 cells by Epimedin C through suppression of mitogen-activated protein kinase activation and increased expression of CDK inhibitors p21(Cip1) and p27(Kip1). Food Chem Toxicol. 44:227–235. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Hao L, Wu J, Zhang J and Su J: Linarin promotes osteogenic differentiation by activating the BMP-2/RUNX2 pathway via protein kinase A signaling. Int J Mol Med. 37:901–910. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Hu H, Long J, Wan F, Li L, Zhang S, Shi YE and Chen Y: Vitexin 6, a novel lignan, induces autophagy and apoptosis by activating the Jun N-terminal kinase pathway. Anticancer Drugs. 24:928–936. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B and Holmgren A: Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. Cancer Res. 66:4410–4418. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Sapkota M, Kim SW and Soh Y: Herbacetin inhibits inducible nitric oxide synthase via JNK and nuclear factor-κB in LPS-stimulated RAW264.7 cells. Eur J Pharmacol. 765:115–123. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cao S, Ni B, Feng L, Yin X, Dou H, Fu J, Lin L and Ni J: Simultaneous determination of typhaneoside and isorhamnetin-3-O-neohesperidoside in rats after oral administration of pollen Typhae extract by UPLC-MS/MS. J Chromatogr Sci. 53:866–871. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shin SW, Jung E, Kim S, Kim JH, Kim EG, Lee J and Park D: Antagonizing effects and mechanisms of Afzelin against UVB-induced cell damage. PLoS One. 8:e619712013. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Zhang X, Cui Y, Zhou H, Xu D, Shan T, Zhang F, Guo Y, Chen Y and Wu D: Taxifolin protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Toxicol Appl Pharmacol. 287:168–177. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chu SC, Chiou HL, Chen PN, Yang SF and Hsieh YS: Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 40:143–149. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimoto E and Yamaguchi M: Stimulatory effect of Daidzein in osteoblastic MC3T3-E1 cells. Biochem Pharmacol. 59:471–475. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KT, Sohn IC, Kim YK, Choi JH, Choi JW, Park HJ, Itoh Y and Miyamoto K: Tectorigenin, an isoflavone of Pueraria thunbergiana Benth., induces differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull. 24:1117–1121. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kim PS, Shin JH, Jo DS, Shin DW, Choi DH, Kim WJ, Park K, Kim JK, Joo CG, Lee JS, et al: Anti-melanogenic activity of schaftoside in Rhizoma Arisaematis by increasing autophagy in B16F1 cells. Biochem Biophys Res Commun. 503:309–315. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Davignon J and Dubuc G: Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc. 120:163–173. 2009.PubMed/NCBI | |
|
Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao GQ and Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 51:2714–2721. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pal S, Ghosh M, Ghosh S, Bhattacharyya S and Sil PC: Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways. Food Chem Toxicol. 83:36–47. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Puccetti L, Acampa M and Auteri A: Pharmacogenetics of statins therapy. Recent Pat Cardiovasc Drug Discov. 2:228–236. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor BA and Thompson PD: Statins and their effect on PCSK9-impact and clinical relevance. Curr Atheroscler Rep. 18:462016. View Article : Google Scholar : PubMed/NCBI | |
|
Cameron J, Ranheim T, Kulseth MA, Leren TP and Berge KE: Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 201:266–273. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A, Ekavali, Chopra K, Mukherjee M, Pottabathini R and Dhull DK: Current knowledge and pharmacological profile of berberine: An update. Eur J Pharmacol. 761:288–297. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J and Sun G: Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 161:69–81. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu JW, Lin LC and Tsai TH: Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 121:185–193. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R and Glodé LM: A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 25:139–146. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stolf AM, Cardoso CC and Acco A: Effects of silymarin on diabetes mellitus complications: A review. Phytother Res. 31:366–374. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 42:1141–1160. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wu JW, Lin LC and Tsai TH: Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 121:185–193. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pang Y, Zhu H, Xu J, Yang L, Liu L and Li J: β-arrestin-2 is involved in irisin-induced glucose metabolism in type 2 diabetes via p38 MAPK signaling. Exp Cell Res. 360:199–204. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cui CJ, Li S, Zhu CG, Sun J, Du Y, Zhang Y, Wu NQ, Guo YL, Xu RX, Gao Y and Li JJ: Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells. J Cell Mol Med. 20:2374–2383. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Du Y, Li S, Cui CJ, Zhang Y, Yang SH and Li JJ: Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: Linking dyslipidemia with obesity. J Transl Med. 14:2762016. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Huang Q, Long X, Zhang J, Huang X, Aa J, Yang H, Chen Z and Xing J: CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways. J Hepatol. 63:1378–1389. 2015. View Article : Google Scholar : PubMed/NCBI |
